Search Target
About the HSRRC


HSRRC Administration

The administrative office of the Human Subjects Research Review Committee is in the Office of Research and Sponsored Programs. The Institutional Official overseeing the activities of the Human Subjects Research Review Committee is Nancy Lewis, Assistant Vice President for Research Compliance. 

HSRRC Members
  • Peter Gerhardstein, PhD, Chair, HSRRC
  • Jiyun Elizabeth (Liz) L. Shin, PhD, Associate Director, HSRRC
  • Eric P. Hoffman, PhD, School of Pharmacy and Pharmaceutical Sciences
  • Suk Young Kang, PhD, Department of Social Work, College of Community and Public Affairs
  • Kenneth Kurtz, PhD, Psychology
  • Shuxia (Susan) Lu, PhD, Watson School of Engineering and Applied Science
  • Melissa Sutherland, PhD, FNP-BC, Decker School of Nursing
  • Pamela Sandoval, PhD, Graduate School of Education
  • Andrew Weisskopf, Chief Information Security Officer & Director of Security Operations
  • Allen D. Alt, MD, Retired Community Physician
  • Rev. Robert J. Sullivan, Religious Advocate (alternate member) 
  • Titilayo Okoror, PhD, Department of Africana Studies, Harpur College (alternate member)


Michele Lukovich is a support staff for the HSRRC, and can be reached at or (607) 777-3818.

  1. The Human Subjects Research Review Committee is charged with certain responsibilities and authority in accordance with institutional policy and federal regulations. These are listed below.

    1. Determine whether a given activity should be considered human subjects research.

    2. Review and approve, require modifications in (to secure approval), or disapprove research activities which involve human subjects.

    3. The HSRRC shall approve research based on the committee's determinations that the following requirements are satisfied:

      1. Risks to subjects are minimized:

        1. by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, and

        2. whenever appropriate by using procedures already being performed on the subjects for diagnostic or treatment purposes.

      2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of knowledge that may reasonably be expected to result. In evaluating risks and benefits, the committee shall consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). The committee shall not consider long-range effects of applying knowledge gained in the research as among those research risks that fall within the purview of its responsibility.

      3. Selection of subjects is equitable. In making this assessment the committee shall take into account the purposes of the research, the setting in which the research will be conducted, and the population from which subjects will be recruited.

      4. Require that information given to subjects as part of informed consent is in accordance with institutional policy and may require that information, in addition to that specifically required by federal regulations be given to the subject when in the committee's judgment, the information would meaningfully add to the protection of the rights and welfare of subjects.

      5. Require documentation of informed consent or waive documentation in accordance with institutional policies in compliance with federal regulations as a minimum.

      6. Where appropriate, the research plan makes adequate provision for monitoring the data collected to insure the safety of subject.

      7. Where appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.

    4. Conduct continuing review of research at intervals appropriate to the degree of risk but not less than once per year, and shall have authority to observe or have a third party observe the consent process and research.

    5. Determine which projects need verification from sources other than the research investigators that no material changes have occurred since the previous HSRRC review.

    6. Report to appropriate institutional officials and, when appropriate, the OPRR, any serious or continuing noncompliance by investigators with the requirements and determinations of the committee.

    7. Suspend or terminate approval of research that is not being conducted in accordance with the committee's requirements or that had been associated with unexpected serious harm to subjects. Any suspension or termination of approval shall include a statement about the committee's action and shall be reported promptly to the investigator, institutional officials and appropriate federal officials, if required.

  2. The HSRRC is appointed with variable term appointments by the associate vice president with the approval of the president.

  3. In compliance with DHHS regulations, the committee is comprised of people from diverse backgrounds and with professional competence necessary to review specific research activities. A variety of professions are represented, including at least one member whose primary expertise is in a nonscientific area and at least one member who is not otherwise affiliated with the institution personally or through an immediate family member.


Federal Wide Assurance

These guidelines are based on and implement the Federal Assurance of Protection of Human Subjects (FWA# 00000174) approved for Binghamton University by the Office of Human Research Protection (OHRP) at the Department of Health and Human Services (DHHS) on 10/24/2017, and expires 10/24/2022.


Human Subjects Research Review Office

Peter Gerhardstein, Chair
Michele Lukovich, IRB Coordinator
ITC Building Room 2204
PO Box 6000
Binghamton NY 13902-6000
Fax: (607) 777-5025
Telephone (607) 777-3818


Questions or Concerns

Investigators and research staff are invited to contact the HSRRC Office to obtain answers to questions, express concerns and convey suggestions regarding the human research protection program.

Last Updated: 1/22/19